Skip to Main Content

Alnylam therapy for increasingly common heart disease succeeds in closely watched trial

Alnylam Pharmaceuticals’ treatment for an increasingly common heart disease succeeded in a closely watched clinical trial, the company said.

Yvonne Greenstreet

After spending her childhood in Ghana, Greenstreet studied in England and went on to become a physician practicing obstetrics and gynecology in the U.K. Later, she earned an MBA from INSEAD, a top-ranked business school in France. She led drug development divisions at pharma giants GlaxoSmithKline and Pfizer before landing at Alnylam as chief operating…

Virtual Event – [email protected]: Will 2022 bring biotech renewal?

Come explore what’s happening in biotech and health tech, and hear the latest about JPM 2022, with STAT’s team of ace reporters.

A preview of the burning biotech and health tech questions at JPM 2022

A rundown of what to look for at this year's J.P. Morgan Healthcare Conference.

Alnylam’s new CEO hopes appointment inspires underrepresented groups

At Alynlam, a new CEO "understands how to push the frontiers of medicine forward.”

Set to retire, Alnylam’s Maraganore reflects on his successor and his next steps

"It was clear that she could roll up her sleeves and do the hard work that was needed," Alnylam's Maraganore said of his successor, Yvonne Greenstreet. #STATSummit

John Maraganore on what comes next for Alnylam and his career

John Maraganore, the longtime CEO of Alnylam Pharmaceuticals, is stepping down after almost 20 years at the company. Maraganore spoke with our "Readout LOUD" hosts this week about his decision.

Up and down the ladder: The latest comings and goings

From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry.

Pharmalittle: Pelosi tries last-ditch drug pricing proposal; Merck sees up to $7B in Covid pill sales in 2022

Merck forecast between $5 billion and $7 billion in sales of its Covid-19 pill through the end of 2022, assuming emergency use authorization is granted by U.S. regulators in December.

Alnylam’s longtime CEO to depart, new leader named

After almost two decades at the helm, John Maraganore is stepping down as Alnylam’s CEO — the second top executive to leave the company in the last 13 months.

STAT+ Conversations: How Covid-19 will change drug development

Industry leaders from the Covid-19 Research and Development Alliance discuss how the pandemic will change the future of drug development. 

Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

A new biotechnology and pharmaceutical industry commitment to patients and the public

We must develop medicines with patients as our primary concern. Doing so will best serve the interests of patients, their caregivers, and health care providers, as well as those of shareholders and society at large.